louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02306239: The Effect of Terlipressin on Intesitnal Function in Septic Shock Patients
Official title: the Surgical Intensive Care Unit
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Terlipressin
Septic Shock
Lead sponsor: First Affiliated Hospital, Sun Yat-Sen University
Sponsor class: OTHER
First posted: 2014-12-03
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Terlipressin becomes a vasopressin for septic shock. But some studies found it may lead to severe intesitnal complications such as intestinal ischemia. The investigators study was designed to find the effect of terlipressin on intestinal function in septic shock patients.


Eligibility criteria: Inclusion Criteria:

* septic shock

Exclusion Criteria:

* shock due to other reasons
* diagnosited intesitinal ischemia

Primary outcomes:
measure: intestinal function assessed by abdominal distension, intestinal bleeding, peritonitis, plasma DAO level, enteral nutrition
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: the First Affiliated Hospital of Sumyetsan University
state: Guangdong
Study officials:
affiliation: the first affiliated hospital of SUMS
name: liu zimeng, master
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04637139: A Study to Evaluate the Mass Balance Absorption and AME of VBR
Official title: An Open Label Phase 1 Study in Healthy Adult Male Subjects to Determine the Mass Balance Recovery, Absorption, Metabolism, and Excretion of [14C] Vebicorvir Following Single Oral Dose Administration
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Chronic Hepatitis B
Keywords: CHB
HBV
hepatitis B
Lead sponsor: Assembly Biosciences
Sponsor class: INDUSTRY
First posted: 2020-11-19
Enrollment: 6
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This Phase 1 Study will determine the mass balance recovery, absorption, metabolism, and excretion of \[14C\] Vebicorvir in healthy male subjects


Eligibility criteria: * Consent
* Male between 18 and 55 years of age (inclusive) at the time of Screening
* Body mass index (BMI) between ≥18.0 kg/m2 and ≤32.0 kg/m2 at Screening; body weight between ≥55.0 kg and ≤100.0 kg at Screening
* Considered to be in good health by the Investigator

Exclusion Criteria:

* History or presence of any condition (e.g., chronic diarrhea) or prior surgery (e.g., gastric bypass)
* Clinically significant abnormal medical history
* History of cancer that has not been in full remission for \>5 years
* Acute illness within 14 days prior to study drug administration

Primary outcomes:
measure: Mass Balance: Cumulative Amount of [14C] Radiolabel Excreted in Urine up to the Last Sampling Interval (Ae-urine, 14C)
timeFrame: Before dosing and at prespecified time intervals up to 168 hours after dosing
measure: Mass Balance: Cumulative Amount of [14C] Radiolabel Excreted in Feces up to the Last Sampling Interval (Ae-feces, 14C)
timeFrame: Before dosing and at prespecified time intervals up to 168 hours after dosing
Secondary outcomes:
measure: Number of Participants with One or More Adverse Events
timeFrame: Up to 168 hours
measure: Number of Participants Discontinued from the Study Due to an Adverse Event
timeFrame: Up to 168 hours
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Pharmaron CPC
state: Maryland
Study officials:
References:
Clinical trial NCT06766539: The Application of Eye-Tracking Technology in Perioperative Management and Education
Official title: The Application of Eye-Tracking Technology in Perioperative Management and Education: a Prospective Observational Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Eye-tracking Technology
Medical Education
Perioperative Management
Attention Distribution
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2025-01-09
Enrollment: 300
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Anesthesiologists, including senior physicians and junior doctors and medical students undergoing perioperative management training.

Brief summary: The goal of this observational study is to explore the value of eye-tracking technology in perioperative management and teaching. The study aims to understand how eye-tracking can help analyze the attention distribution of clinicians during perioperative procedures and optimize workflows for improved safety and teaching outcomes.

The main questions it seeks to answer are:

How does eye-tracking technology reveal the focus distribution patterns of experienced and novice clinicians in perioperative scenarios? Can visualizing expert clinicians' eye movement patterns improve the learning outcomes and operational skills of medical students?

Participants include anesthesiologists and medical students involved in perioperative management training. Eye-tracking data, such as fixation duration, fixation count, and heatmaps, will be collected during surgical and training scenarios. The study will analyze correlations between attention distribution and operational performance. This research will provide insights into optimizing perioperative safety and revolutionizing medical education using objective attention data.


Eligibility criteria: Inclusion Criteria:

* Anesthesiologists, including senior physicians and junior doctors.
* Medical students undergoing perioperative management training.

Exclusion Criteria:

* Individuals with ophthalmological conditions that affect eye movement function.
* Participants who fail to complete the full experimental protocol.

Primary outcomes:
measure: Identify the "hotspots" where anesthesiologists focus their attention within different areas of the anesthesia machines.
timeFrame: 1 year
Secondary outcomes:
measure: The percentage of time anesthesiologists' eyes attention.
timeFrame: 1 year
measure: Attention of the clinician
timeFrame: 1 year
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
state: Zhejiang
Study officials:
References:
Clinical trial NCT00579839: Trial of Immediate vs. Delayed Cord Clamping in the Preterm Neonate
Official title: A Randomized Controlled Trial of Immediate Versus Delayed Cord Clamping in the Preterm Neonate
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: PreTerm Birth
PreTerm Neonate
Keywords: PreTerm Birth
PreTerm Neonate
High risk pregnancy
Preterm Baby
Premature Baby
Cord Clamping
Milking the cord
Lead sponsor: University of Oklahoma
Sponsor class: OTHER
First posted: 2007-12-24
Enrollment: 200
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: To determine the short and long term effects of placental transfusion at birth by milking and delayed cord clamping of the umbilical cord in neonates born between 24 weeks 0 days and 34 weeks 0 days weeks' gestation.

Detailed description: This study is intended to be a randomized controlled trial comparing immediate cord clamping which represents the current standard of care at Oklahoma University Medical Center with delayed cord clamping among preterm neonates born between 24 weeks and 34 weeks 0 days weeks' gestation. Allocation sequence will be generated by simple randomization using random number table in the stratum 24-28 weeks 6 days and 29 weeks to 34 weeks 0 days weeks' gestation stratum.

Eligibility criteria: Inclusion Criteria:

* Singleton pregnancies
* Signed consent to participate in the trial

Exclusion Criteria:

* Major fetal anomaly or known fetal chromosomal abnormalities
* Multiple gestation
* Mothers with pregestational and gestational diabetes
* Refusal to participate in the trial

Primary outcomes:
measure: To determine the short and long term effects of placental transfusion at birth by milking and delayed cord clamping of the umbilical cord in neonates born between 24 weeks 0 days and 34 weeks 0 days weeks' gestation.
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Oklahoma City
country: United States
facility: University of Oklahoma Health Sciences Center
state: Oklahoma
Study officials:
affiliation: University of Oklahoma
name: Andrew Elimian, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Elimian A, Goodman J, Escobedo M, Nightingale L, Knudtson E, Williams M. Immediate compared with delayed cord clamping in the preterm neonate: a randomized controlled trial. Obstet Gynecol. 2014 Dec;124(6):1075-1079. doi: 10.1097/AOG.0000000000000556.
Clinical trial NCT02425839: Assessment of Correlation Between Changes of Shear Wave Elastography and Surface Electromyogram of the Masseter
Official title: Assessment of Correlation Between Changes of Shear Wave Elastography and Surface Electromyogram of the Masseter, in Rest and Maximal Voluntary Contraction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Masseter Muscle Spasm
Keywords: shear wave elastography
surface electromyogram
masseter
Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne
Sponsor class: OTHER
First posted: 2015-04-24
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: Diagnoses and follow up of muscles diseases lack imaging. Severity assessment of masticatory dysfunction and follow up of treatment effectiveness is currently based only on clinical features. Supersonic ShearWave Imaging® is a new, non-invasive, non-irradiating and dynamic imaging technique that uses ultrasound and allows shear wave elastic modulus in a muscle in order to study its viscoelastic properties.

In this study, the investigators study the correlation between changes of shear wave elastography modulus and surface electromyogram features of the masseters between rest and maximal voluntary contraction.


Eligibility criteria: Inclusion Criteria:

* People with social security.
* People aged 20 to 40 years, of both sexes.
* People that gave and signed consent to participate in the study.

Exclusion Criteria:

* Any concomitant muscle disease (myopathy, myositis...)
* Botulinum toxin injections in the masseter in the last 3 months preceding the study.
* Any treatment that induces muscular effect (baclofen, benzodiazepine)
* Bruxism or any masticatory apparatus disease
* Any surgery of the masticatory apparatus

Primary outcomes:
measure: Elastic modulus using Supersonic Shear Imaging® technique on superficial and deep masseter parts at rest and maximal voluntary contraction.
timeFrame: Day 1 (inclusion day)
Secondary outcomes:
measure: Thickness of the whole masseter mesured by Supersonic Shear Imaging® technique
timeFrame: Day 1 (inclusion day)
measure: Thickness of the masseter superficial part mesured by Supersonic Shear Imaging® technique
timeFrame: Day 1 (inclusion day)
measure: Thickness of the masseter deep part mesured by Supersonic Shear Imaging® technique
timeFrame: Day 1 (inclusion day)
Other outcomes:
Locations:
city: Saint-Etienne
country: France
facility: CHU de Saint-Etienne
Study officials:
affiliation: CHU de SAINT-ETIENNE
name: Claire BOUTET, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00534339: EasyBand GOAL Trial
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Morbid Obesity
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2007-09-24
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Safety, effectiveness, and performance of Allergan's EasyBand telemetrically adjustable gastric banding device for the treatment of morbidly obese patients.


Eligibility criteria: Inclusion Criteria:

* Minimum 3 year history of morbid obesity with documented failure of conservative, non-surgical means of weight reduction within 1 year prior to the screening visit;
* BMI \>/= 40 kg/m2, or BMI \>/= 35 kg/m2 and \</= 40 kg/m2 with one or more significant medical conditions related to obesity;
* Candidate for surgical weight loss intervention

Exclusion Criteria:

* Previous surgical treatment of obesity;
* Patient already implanted with a device sensitive to radiofrequency emissions (implantable pacemaker, implantable defibrillator, etc);
* Physical or emotional conditions that may prohibit surgery

Primary outcomes:
measure: Percent excess weight loss (%EWL)
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: USA
country: United States
state: California
city: Canada
country: Canada
state: Quebec
Study officials:
affiliation: Allergan Medical
name: Allergan Medical
role: STUDY_DIRECTOR
References:
Clinical trial NCT03272139: Interscalene Block Versus Superior Trunk Block
Official title: Interscalene Block Versus Superior Trunk Block: A Randomized Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Joint Disease
Pain
Pain, Acute
Pain, Chronic
Lead sponsor: Hospital for Special Surgery, New York
Sponsor class: OTHER
First posted: 2017-09-05
Enrollment: 126
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Sparing the phrenic nerve by administering ultrasound-guided low volume superior trunk block (STB) and interscalene block (ISB) for arthroscopic shoulder surgery (labral repair, stabilization, rotator cuff repair).


Eligibility criteria: Inclusion Criteria:

* Patients who will be undergoing primary unilateral labral repair/stabilization of the shoulder
* Age 18 to 80 years
* Planned use of general anesthesia with LMA and interscalene or superior trunk block
* Ability to follow study protocol
* English speaking
* ASA I - III

Exclusion Criteria:

Pre-existing neuropathy of the operative limb

* Younger than 18 years old and older than 80
* Patients with pulmonary severe respiratory disease
* Allergy to one of the study medications
* Chronic gabapentin/pregabalin use (regular use for longer than 3 months)
* Chronic opioid use (taking opioids for longer than 3 months)
* Contraindication to general anesthesia, interscalene or superior trunk block
* Herniated Cervical Disk, Cervical Myelopathy
* BMI \>35

Primary outcomes:
measure: Number of Participants With Incidence of Hemidiaphragmatic Paralysis (HDP)
timeFrame: Day of Surgery, diagnosis confirmed from trained anesthesiologist ultrasound readers
measure: Numerical Pain Rating System (NRS) Pain Scores
timeFrame: Average pain scores at rest recorded Day of Surgery every 30 minutes until discharge according to Post Anaesthetic Discharge Scoring System
Secondary outcomes:
measure: Block Duration
timeFrame: Time of block wearing off recorded on Post Operative Day 1 and Post Operative Day 2 as reported via patient phone call.
Other outcomes:
Locations:
city: New York
country: United States
facility: Hospital for Special Surgery
state: New York
Study officials:
affiliation: Hospital for Special Surgery, New York
name: David H Kim, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05051839: Validation Use of Implants and Abutments With Biologically Oriented Preparation Technique
Official title: Randomized Clinical Trial to Validate Use of Implants and Abutments With Biologically Oriented Preparation Technique (I.B.O.P.T.)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dental Implant-Abutment Design
Lead sponsor: Universidad Complutense de Madrid
Sponsor class: OTHER
First posted: 2021-09-21
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This randomized clinical trial aims to validate and to establish indications for using implants with biological oriented preparation technique (I.B.O.P.T.) for implant supported prosthetic treatment as an option looking for better stability and control of associated soft and hard tissues compared with conventional implants and conventional abutments with finishing lines preparation technique.


Eligibility criteria: Inclusion Criteria:

* Male or female ≥18 years old.
* Need for implant-supported fixed prosthesis in the posterior area of the upper or lower jaw (up to 2 implants and three units bridge);
* Adequate bone quality and quantity at the implant site to allow the insertion of Sweden and Martina Premium or Prama (Due Carrare, Padova, Italy), of diameters 3.8, 4.25 or 5 mm and lengths between 10 and 13 mm.
* Healthy ASA type I and II patients.
* Full-mouth plaque index \<20.

Exclusion Criteria:

* Smokers ≥10 cigarettes/day.
* Presence of implant-supported restorations adjacent to the study site.
* Active periodontitis defined as the presence of pockets with probing depth (PD) ≥5 mm and bleeding on probing (BoP).
* Systemic medication that contraindicates surgery (bisphosphonates or steroid therapy).
* Uncontrolled diabetes.
* Severe bruxism.
* Pregnancy.
* Previous history of radiotherapy.

Primary outcomes:
measure: Marginal bone level
timeFrame: Baseline to 12-months follow-up
measure: Soft tissue volumetric analysis
timeFrame: Baseline to 12-motnhs follow-up
Secondary outcomes:
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: Faculty of Dentistry, Unviersidad Complutense de Madrid
Study officials:
References:
Clinical trial NCT06068439: Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic Nephropathy
Official title: A Phase III Multi-center Randomized Placebo-controlled Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
PHASE3
Conditions: Diabetic Nephropathy Type 2
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2023-10-05
Enrollment: 355
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a multicenter, randomized, placebo-controlled study to evaluate the effectiveness and safety of low-dose aspirin (50 mg/day) in renal and cardiac function protection in people with diabetic nephropathy.


Eligibility criteria: Inclusion Criteria:

* 1.Voluntarily sign informed consent;2.Meet the diagnosis of diabetic nephropathy: In the case of identifying diabetes as the cause of kidney damage and excluding chronic kidney disease caused by other causes, at least one of the following is present:①. In the case of excluding interference factors, at least 2 UACR≥30mg/g or UAER≥30mg/24h (≥20ug/min) in 3 tests within 3\~6 months. ②. eGFR\<60ml/min/(1.73m2)-1 for more than 3 months. ③. Renal biopsy consistent with pathological changes of DKD;3.DKD staging is 3 and before，eGFR\>30ml/min/(1.73m2)-1；

Exclusion Criteria:

* (1) History of cardiovascular or cerebrovascular events (defined by the patient's medical history and/or instrumental examination results); (2)Insufficient glycemic control (i.e., glycated hemoglobin ≥8%); (3) Uncontrolled blood pressure despite taking antihypertensive drugs (≥140/≥85mmHg); (4) Previous major bleeding (i.e., intracranial hemorrhage); (5) Previous gastrointestinal ulcers; (6) Clinical diagnosis of type 1 diabetes mellitus (diagnosis of diabetes mellitus and use of insulin before age 35);(7) Patients with CKDG4 or G5 (i.e., eGFR\<30 mL/min/1.73 m2 or dialysis) ;(8) chronic active infection or; (9) evidence of malignancy within the past 5 years. Patients with tumour disease in situ who are successfully treated only by local resection can be included in the study (including non-melanoma skin cancer in situ); (10) Autoimmune diseases; (11) Persistent arrhythmias requiring anticoagulation therapy (i.e., atrial fibrillation). In this category, isolated ventricular/supraventricular presystoles; (12) Use of NSAIDs or other antiplatelet drugs in the past 30 days; (13) cirrhosis of any etiology; (14) use of anticoagulants; (15) Life expectancy less than 1 year; (16) Known aspirin allergy; (17) Known pregnancy; and (18) Severe mental illness.

Primary outcomes:
measure: decline of renal function
timeFrame: 3YEARS
Secondary outcomes:
measure: The rapid decline in renal function
timeFrame: 3YEARS
measure: Change of renal function class
timeFrame: 3YEARS
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01248039: Preoperative Pain, Function, and Activity for Total Hip and Knee Arthroplasty Patients
Official title: The Influence of Preoperative Pain, Function, and Activity on Time to Fulfill Discharge Criteria for Total Hip and Knee Arthroplasty Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Arthroplasty
Keywords: Muscle strength, functional performance, joint replacement
Lead sponsor: Hvidovre University Hospital
Sponsor class: OTHER
Collaborators: name: Lundbeck Foundation
First posted: 2010-11-25
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Concesutive hip and knee arthroplasty patients from a department of orthopaedic surgery

Brief summary: This study wish to show if the preoperative level of pain, function or activity for hip and knee arthroplasty patients has any predictive value of the time it takes to fulfill the well-defined discharge criteria.

Detailed description: The investigators would like to be able to identify those patients, for whom it will take longest time to fulfill the discharge criteria. With this knowledge the investigators will be able to initiate sufficient treatment already before operation.

Eligibility criteria: Inclusion Criteria:

* Total hip arthroplasty patients
* Total knee arthroplasty patients

Exclusion Criteria:

* Inability to speak and understand Danish
* Inability to perform the functional measurements due to other conditions

Primary outcomes:
measure: Leg muscles strength
timeFrame: 7 months
Secondary outcomes:
measure: Functional performance
timeFrame: 7 months
Other outcomes:
Locations:
city: Hvidovre
country: Denmark
facility: Department of Surgery, Univerity Hospital at Hvidovre
Study officials:
affiliation: The Lundbeckcenter for hip and knee surgery, University Hospital at Hvidovre, Kettegaard Allé 30, DK-2650 hvidovre, Denmark
name: Bente Holm, MSc
role: PRINCIPAL_INVESTIGATOR
References:
citation: Holm B, Bandholm T, Lunn TH, Husted H, Aalund PK, Hansen TB, Kehlet H. Role of preoperative pain, muscle function, and activity level in discharge readiness after fast-track hip and knee arthroplasty. Acta Orthop. 2014 Sep;85(5):488-92. doi: 10.3109/17453674.2014.934186. Epub 2014 Jun 23.